Emerald Clinics, is to rebrand as Emyria Limited.
The company said the name change is “consistent with its global ambitions and expanded offerings”.
Shares soared almost 30% on the news, to close at $0.079. Emerald listed on the ASX earlier this year, reaching a share high of $0.14 in February.
The name change, which must be approved by shareholders at a general meeting next month, comes after Emerald signed a deal with Spectrum Biomedical UK (SBUK), the UK subsidiary of the world’s largest cannabis company Canopy Growth, to develop a Real-World Evidence system.
More at. https://www.cannabiz.com.au/emerald-clinics-to-rebrand-as-emyria-to-reflect-global-ambition/?utm_medium=email&utm_campaign=Cannabiz%20newsletter%202082020&utm_content=Cannabiz%20newsletter%202082020+CID_12c3f6e423e25ec012ea3a579246991b&utm_source=CampaignMonitor&utm_term=Emerald%20Clinics%20to%20rebrand%20as%20Emyria%20to%20reflect%20global%20ambition